Polyquisteic Liver Disease

Manifestations of poliquistosis hepática in ADPKD pacientes, síntoma management, and tratamiento options.

⚠ Medical Safety Notice

This website provides health education for ADPKD pacientes and their families. It does not provide diagnóstico, prescriptions, dosing, or individualized tratamiento plans. Always discuss medical decisions with your nefrólogo. In emergencies, busque atención médica inmediata or call your local emergency number.

What is Polyquisteic Liver Disease

Polyquisteic hígado disease (PLD) is the most common extrarenal manifestation of ADPKD, affecting approximately 70–80% of ADPKD pacientes. Liver quistes typically do not affect hígado function, but very large quistes can cause abdominal bloating, pain, and early satiety.

Characteristics

When to Seek Medical Care

⚠ Emergency Signs

Sudden severe right upper quadrant pain with fiebre may indicate infección de quiste or hemorrhage. Seek atención médica inmediata.

Management Approaches

Conservative Management (Most Patients)

Intervention Options for Symptomatic Patients

When quistes cause significant síntomas, physicians may consider the following options (all require physician evaluation):

Special Note

Female ADPKD pacientes using estrogen-containing contraceptives or hormona replacement therapy may accelerate hígado crecimiento de quistes. Discuss contraceptive options with your physician — progestin-only or non-hormonal methods may be considered.

References

  1. KDIGO 2025 Clinical Practice Guideline on the Evaluation and Management of Autosomal Dominant Polyquisteic Kidney Disease (ADPKD) — KDIGO. Kidney International, 2025. DOI: 10.1016/j.kint.2024.07.010. View source
  2. Chinese Guideline for the Diagnosis and Treatment of Autosomal Dominant Polyquisteic Kidney Disease (2024 Edition) — Chinese Society of Nephrology, Chinese Medical Association. Chinese Journal of Nephrology, 2024. View source
  3. Pansomatoestatinaa Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polyquisteic Kidney or Liver Disease with Severe Liver Involvement — Hogan MC, et al. Clinical Journal of the American Society of Nephrology, 2020. DOI: 10.2215/CJN.13661119. View source
  4. Long-acting somatoestatinaa analogues for poliquistosis hepática (RCT) — van Keer IM, et al. Lancet Gastroenterol Hepatol, 2023. DOI: 10.1016/S2468-1253(23)00100-0. View source
  5. ADPKD: Epidemiology, Pathophysiology and Management — Temple R, et al. Nature Reviews Nephrology, 2023. View source
Evidence level: A (current guías and high-quality evidencia)
Limitations: This content Individual circumstances vary greatly — always consulte a su nefrólogo.

← Back to Knowledge Base